Bionxt Solutions Inc BNXTF

$0.22 +0.00 (1.88%)

Valuation

Market cap: 30,213,000
Revenue TTM: $0
Net income TTM: $-5,030,000
PE ratio: 0.00
Forward PE: —
Profit margin: 0.00%
Debt to equity: -0.89

Trading

Volume: 10,400
Avg volume: 4,590
Day's range: $0.22 – $0.23
Shares out: 136,093,000
Stochastic %K: 70%
Beta: 0.70
Analysts: Strong Buy
Price target: $2.00

Price

Company profile

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 780-818-6422
Website: https://www.bionxt.com
Address: 1928 Linden Road, Vancouver, Canada

Latest news

No headlines yet.

Stocktwits

MakingDreamsReality Jul 17, 12:23 PM

PM mOOvers 👀 $LGVN - Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer's Disease $GDTC - CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers $ADTX -Aditxt And Evofem Amend Merger Agreement, Aiming For September 30 Closure; Evofem Acquires FDA-Approved SOLOSEC $WD -Reported Earlier, Walker & Dunlop Arranges $167M Sale Of Millennium PQ, Second Largest Single-Asset Sale In California For 2024 $BNXTF -BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development

0 replies

NetworkNewsWire Mar 14, 7:20 PM

BioMedNewsBreaks – $BNXT.CN $BNXTF $BXT.F Announces Highly Promising Results from ODF Cladribine PK Study https://ibn.fm/eXd9A

0 replies

Stock_Titan Dec 22, 12:52 AM

$BNXTF BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing

0 replies

Stock_Titan Nov 25, 1:07 AM

$BNXTF Bionxt Solutions Announces Convertible Debenture and Interest Settlement Article Available on StockTitan Website.

0 replies

Stock_Titan Nov 20, 8:06 AM

$BNXTF BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament Article Available on StockTitan Website.

0 replies

Stock_Titan Nov 15, 8:06 AM

$BNXTF BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program Article Available on StockTitan Website.

0 replies

Stock_Titan Nov 13, 8:06 AM

$BNXTF BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis https://www.stocktitan.net/news/BNXTF/bio-nxt-signs-definitive-agreement-for-100-acquisition-of-ip-and-co-xu5udv2qrrt3.html

0 replies

Stock_Titan Nov 6, 8:06 AM

$BNXTF BioNxt Solutions Reports on Barcelona CPHI Conference https://www.stocktitan.net/news/BNXTF/bio-nxt-solutions-reports-on-barcelona-cphi-sl5271u3t2v7.html

0 replies